← Back to Search

Small Molecule

MW189 for Brain Bleed (BEACH Trial)

Phase 2
Recruiting
Led By Linda J. Hanley
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to receive first dose of test article within 24h after onset of ICH symptoms
Controlled blood pressure (systolic BP < 180 mm Hg) at randomization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days post-randomization
Awards & highlights

BEACH Trial Summary

This trial will study if a new medication is safe and tolerated in patients with a brain bleed.

Who is the study for?
This trial is for adults with a confirmed diagnosis of spontaneous, non-traumatic brain bleeding (ICH) who can start treatment within 24 hours after symptoms begin. They must have a certain level of consciousness and stable blood pressure, not be pregnant or lactating, and cannot have severe liver or kidney issues or infections.Check my eligibility
What is being tested?
The BEACH study is testing the safety of MW189 compared to saline in patients with brain hemorrhage. It's a phase 2a pilot study where participants are randomly chosen to receive either MW189 or saline to see how well they tolerate it.See study design
What are the potential side effects?
While specific side effects for MW189 aren't listed, common risks may include reactions at the injection site, potential allergic responses, and general discomfort. The trial aims to assess these side effects thoroughly.

BEACH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can start the trial treatment within 24 hours after my stroke symptoms began.
Select...
My blood pressure is under 180 mm Hg.
Select...
I have been diagnosed with a brain bleed that wasn't caused by an injury.
Select...
I am 18 years old or older.
Select...
I am not scheduled for any surgery except for an external ventricular drain (EVD).
Select...
My brain bleed is between 10 and 60 mL in volume, confirmed by CT scans.
Select...
I can have needles inserted without difficulty.

BEACH Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days post-randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days post-randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in the proportion of all cause-morality between arms

BEACH Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ExperimentalExperimental Treatment1 Intervention
MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Group II: ControlPlacebo Group1 Intervention
Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,263 Previous Clinical Trials
14,823,045 Total Patients Enrolled
34 Trials studying Stroke
28,922 Patients Enrolled for Stroke
University of KentuckyOTHER
186 Previous Clinical Trials
226,564 Total Patients Enrolled
5 Trials studying Stroke
145 Patients Enrolled for Stroke
National Institute on Aging (NIA)NIH
1,673 Previous Clinical Trials
28,020,723 Total Patients Enrolled
16 Trials studying Stroke
27,846 Patients Enrolled for Stroke

Media Library

MW189 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05020535 — Phase 2
Stroke Research Study Groups: Experimental, Control
Stroke Clinical Trial 2023: MW189 Highlights & Side Effects. Trial Name: NCT05020535 — Phase 2
MW189 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05020535 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you inform us of any other research done on MW189?

"As of now, there is 1 active study investigating MW189 with 0 trials in Phase 3. While many of the studies for MW189 are located in Lexington, Kentucky, there are 9 locations operating studies for MW189."

Answered by AI

How many people are allowed to sign up for this experiment?

"That is correct. The information available on clinicaltrials.gov indicates that this study, which was first announced on October 10th, 2020, is still seeking patients. In total, 120 individuals are needed across 9 different locations for the trial."

Answered by AI

Are people still able to sign up for this experiment?

"If you are interested in participating in this clinical trial, you may be eligible! The trial was posted on October 10th, 20202 and updated on October 11st, 20202."

Answered by AI

Has MW189 undergone FDA approval proceedings?

"While there is some data backing MW189's safety, it remains unproven in terms of efficacy. Therefore, it received a score of 2."

Answered by AI

Is this study prominent in Canada?

"The trial is based in New york University Grossman School of Medicine, situated in Brooklyn. However, there are also 9 other locations across the states of New mexico and Connecticut."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
2022. "Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05020535.
~63 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top